Obesity researchers meet this weekend at ObesityWeek, which runs from 14 to 17 November near Washington, D.C. Novo Nordisk alone is presenting 26 abstracts, including new results for CagriSema, the combination it hopes US regulators will approve before the end of the year. It is a good moment to step back. In a little over 40 years, a family of gut hormone peptides has gone from a laboratory puzzle to the most closely watched class of medicines in the world.
This is how that happened, told through the discoveries, the approvals and the setbacks, and where the next generation stands in November 2026.
A hormone hidden inside the glucagon gene
The story starts in 1982 at Massachusetts General Hospital, where Joel Habener cloned the gene for glucagon and found that it also encoded a second molecule, glucagon-like peptide 1, or GLP-1. Svetlana Mojsov, working independently, identified which form of the peptide is active in the body, GLP-1 (7-37). In 1987 she, Habener and Gordon Weir showed that tiny amounts of it, at the levels found in blood, made the pancreas release insulin.
There was a catch. Natural GLP-1 is broken down within minutes, with a half life of about 1.5 minutes after an injection into a vein. A hormone that disappears that fast is close to useless as a medicine.
The lizard that solved the first problem
The first answer came from the desert. John Eng, an endocrinologist at the Veterans Affairs medical centre in the Bronx, was screening animal venoms for new hormones. In 1992 he found a peptide in the venom of the Gila monster, a slow, venomous lizard from the American Southwest, and named it exendin-4. It acted like GLP-1 but survived far longer in the blood.
According to The Telegraph, the Veterans Affairs department declined to patent the discovery because it did not address an ailment specific to veterans. Eng pursued it himself, and the work was later licensed to Amylin Pharmaceuticals. In April 2005 the US Food and Drug Administration approved exenatide, a synthetic copy of exendin-4, as Byetta, developed by Amylin and Eli Lilly. It was the first medicine of its kind, a twice daily injection for type 2 diabetes.
The fatty acid trick
The second answer came from Denmark. At Novo Nordisk, Lotte Bjerre Knudsen's team attached fatty acid chains to GLP-1 so that it would travel through the bloodstream bound to albumin, the most common protein in blood, shielded from enzymes and from filtering by the kidneys. That approach led to liraglutide and later to semaglutide.
Semaglutide was approved for type 2 diabetes as Ozempic in 2017. On 4 June 2021 the FDA approved a higher dose, Wegovy, for chronic weight management, the first new drug for that use since 2014. In November 2023 the SELECT trial of 17,604 people with overweight or obesity and heart disease, but no diabetes, found that major cardiovascular events fell from 8.0 percent on placebo to 6.5 percent on semaglutide, a 20 percent relative reduction. In September 2024 Habener, Mojsov and Knudsen shared the Lasker award for clinical medical research.
Two hormones, then three
Eli Lilly's next step was to hit more than one receptor with a single molecule. Tirzepatide acts on the receptors for GLP-1 and GIP, a second gut hormone. Approved for weight management as Zepbound on 8 November 2023, it produced average weight loss of 20.9 percent at the top dose after 72 weeks in the SURMOUNT-1 trial.
Retatrutide adds a third target, the glucagon receptor. In a phase 2 trial published in 2023, the highest dose cut weight by 24.2 percent after 48 weeks, against 2.1 percent on placebo. This year it delivered in phase 3. In TRIUMPH-1, which randomised 2,339 adults, people on 12 mg who stayed on treatment lost 28.3 percent of their weight at 80 weeks. Counting everyone, whether or not they kept taking it, the figure was 25.0 percent, against 3.9 percent on placebo. In an extension for people with a BMI of 35 or more, weight loss reached 30.3 percent at 104 weeks.
The side effects show the price. On 12 mg, 11.3 percent stopped because of adverse events, against 4.9 percent on placebo, and 12.5 percent reported dysesthesia, an abnormal skin sensation, against 0.9 percent. Two more phase 3 trials reported in July, with weight loss of up to 20.8 percent in people with type 2 diabetes and 22.6 percent in people with heart disease. Lilly plans to file with the FDA in the first quarter of 2027.
Pills, including one that is not a peptide
On 22 December 2025 the FDA approved a once daily semaglutide tablet, the Wegovy pill, as the first oral GLP-1 medicine for obesity. Because semaglutide is a peptide, the tablet has to be taken in the morning on an empty stomach with a sip of water, followed by a 30 minute wait before eating or drinking.
Lilly's orforglipron, approved as Foundayo on 1 April 2026 after a 50 day review, breaks the pattern. It is a small molecule that switches on the GLP-1 receptor without being a peptide at all, and it can be taken at any time of day. In the 72 week ATTAIN-1 trial the top dose produced 12.4 percent weight loss in people who stayed on treatment, against 0.9 percent on placebo, or 11.1 percent against 2.1 percent across all participants. For the first time, a non-peptide drug competes directly with the peptides.
The patent clock
2026 is also the year semaglutide went generic in parts of the world. In Canada, Novo's patent lapsed early after a 450 dollar maintenance fee went unpaid in 2019, The Logic reported. Key patents in India and China expired in March. Several generic versions launched in India that month, and Health Canada approved its first generic semaglutide, from Dr Reddy's, at the end of April. Apotex and Dr Reddy's both launched in Canada in mid May.
In the United States, Apotex received a tentative FDA approval in April for a generic version that can launch only once Novo's US exclusivity ends. Generic semaglutide is not yet sold in the US.
The amylin wave and the next contenders
The newest bets add amylin, a hormone released alongside insulin that signals fullness. Novo filed CagriSema, a weekly combination of semaglutide with the amylin analogue cagrilintide, with the FDA in December 2025. In February its open label REDEFINE 4 trial against tirzepatide missed its goal: among people who stayed on treatment, weight loss at 84 weeks was 23.0 percent on CagriSema against 25.5 percent on tirzepatide. Novo still expects an FDA decision by late 2026 and is presenting lower dose results at ObesityWeek.
Novo's amycretin, a single molecule that acts on both GLP-1 and amylin receptors, produced 22 percent weight loss after 36 weeks in an early trial and entered phase 3 this year. Lilly reported up to 23.3 percent weight loss when its amylin drug eloralintide was combined with tirzepatide in a phase 2 trial, and Roche and Zealand Pharma's petrelintide is in phase 3. Amgen is testing maridebart cafraglutide, an antibody joined to two GLP-1 peptides and given once a month, in a phase 3 programme.
What is still unknown
No trial has compared retatrutide with CagriSema, amycretin or any other next generation drug, so rankings drawn from separate trials are guesses. Much of the 2026 data comes from company reported topline results that have not yet been peer reviewed.
Long term safety is the bigger open question. Semaglutide has a cardiovascular outcomes trial behind it; the triple agonists do not yet. In TRIUMPH-3, which enrolled people with heart disease, there were 27 major cardiovascular events on retatrutide against 23 on placebo, a hazard ratio of 1.12 with wide uncertainty, too few events to draw a conclusion either way. Why dysesthesia appears with retatrutide has not been explained. And whether the FDA approves CagriSema this year, and with what label, is still to be decided.